Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 17, 2017 - Issue 9
Submit an article Journal homepage
1,316
Views
12
CrossRef citations to date
0
Altmetric
Editorial

Future perspectives for personalized immunotherapy in renal cell carcinoma

Chiara CiccareseMedical Oncology, University Hospital of Verona, Verona, ItalyView further author information
,
Vincenzo Di NunnoDivision of Oncology, S.Orsola-Malpighi Hospital, Bologna, ItalyView further author information
,
Roberto IacovelliMedical Oncology, University Hospital of Verona, Verona, ItalyView further author information
&
Francesco MassariDivision of Oncology, S.Orsola-Malpighi Hospital, Bologna, ItalyCorrespondence[email protected]
View further author information
Pages 1049-1052 | Received 02 Apr 2017, Accepted 02 Jun 2017, Published online: 07 Jun 2017

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Andrea Muto & Cesare Gridelli. (2019) New immunotherapy in the treatment of advanced renal cancer. Expert Opinion on Emerging Drugs 24:4, pages 233-237.
Read now

Articles from other publishers (11)

Ping Wu, Tingting Xiang, Jing Wang, Run Lv, Shaoxin Ma, Limei Yuan, Guangzhen Wu & Xiangyu Che. (2021) Identification of immunization-related new prognostic biomarkers for papillary renal cell carcinoma by integrated bioinformatics analysis. BMC Medical Genomics 14:1.
Crossref
Wei Shi, Xiaomei Yang, Shenxia Xie, Dani Zhong, Xuandong Lin, Ziqiang Ding, Siliang Duan, Fengzhen Mo, Aiqun Liu, Shihua Yin, Xiaobing Jiang, Zhi Ping (Gordon) Xu & Xiaoling Lu. (2021) A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. Cancer Letters 522, pages 184-197.
Crossref
Francesco Massari, Vincenzo Di Nunno, Veronica Mollica, Rodolfo Montironi, Liang Cheng, Alessia Cimadamore, Ana Blanca & Antonio Lopez-Beltran. (2019) Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy 11:17, pages 1507-1521.
Crossref
Francesco Massari, Vincenzo Di Nunno, Matteo Santoni, Lidia Gatto, Claudia Caserta, Franco Morelli, Elena Zafarana, Francesco Carrozza, Alessandra Mosca, Veronica Mollica, Roberto Iacovelli, Roberto Sabbatini, Camillo Porta & Sergio Bracarda. (2019) Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology 142, pages 141-152.
Crossref
Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi & Francesco Massari. (2019) Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers 11:6, pages 830.
Crossref
Francesco Massari, Vincenzo Di Nunno, Veronica Mollica, Jeffrey Graham, Lidia Gatto & Daniel Heng. (2019) Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials. Clinical Genitourinary Cancer 17:2, pages e339-e344.
Crossref
Francesco Massari & Vincenzo Di Nunno. (2019) CheckMate 214 patient-reported outcomes: listening to our patients. The Lancet Oncology 20:2, pages 179-180.
Crossref
Vincenzo Di Nunno, Lidia Gatto, Benedetta Fragomeno, Marta Cubelli, Elisabetta Nobili, Ida Romano, Matteo Santoni, Salvatore Pisconti, Rodolfo Montironi & Francesco Massari. (2018) Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?. Future Oncology 14:29, pages 2997-2999.
Crossref
Veronica Mollica, Vincenzo Di Nunno, Beniamino Corcioni, Michelangelo Fiorentino, Elisabetta Nobili, Riccardo Schiavina, Rita Golfieri, Eugenio Brunocilla, Andrea Ardizzoni & Francesco Massari. (2018) A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. Anti-Cancer Drugs 29:9, pages 911-913.
Crossref
N. E. Kushlinskii, M. V. Fridman, A. A. Morozov, E. S. Gershtein, Z. G. Kadagidze & V. B. Matveev. (2018) Modern approaches to kidney cancer immunotherapy. Cancer Urology 14:2, pages 54-67.
Crossref
Harvey Yu-Li Su. (2018) Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer 16:2, pages 114-116.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.